Inclusion Criteria:

          -  Pathologically (histologically) proven diagnosis of non-muscle invasive (Ta, Tis, or
             T1) bladder cancer within 90 days prior to enrollment

          -  Able to give informed consent

          -  18 years or older

          -  Patients must not be taking oral glucocorticoids at the time of registration

          -  Not have active, uncontrolled infections

          -  No other prior non-bladder malignancy is allowed except for the following: adequately
             treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately
             treated Stage I or II cancer from which the patient is currently in complete
             remission, or any other cancer from which the patient has been disease free for five
             years.

          -  Patients with localized prostate cancer who are being followed by an active
             survelillance program are also eligible.

          -  Patients must not be pregnant or nursing, as the use of Intravesical BCG is not
             recommended during pregnancy. Women/ men of reproductive potential must have agreed to
             use an effective contraceptive method. A woman is considered to be of "reproductive
             potential" if she has had menses at any time in the preceding 12 consecutive months.
             Examples of effective contraception include hormonal contraception, double barrier
             method (condom with spermicidal cream, diaphragms with spermicidal cream, or condoms
             with diaphragms), Intrauterine device, and/or partner vasectomy. In addition to
             routine contraceptive methods, "effective contraception" also includes heterosexual
             celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy
             prevention) defined as a hysterectomy, bilateral oophorectomy, or bilateral tubal
             ligation. However, if at any point a previously celibate patient chooses to become
             heterosexually active during the time period for use of contraceptive measures
             outlined in the protocol, he/she is responsible for beginning contraceptive measures.
             Both male and female patients will be required to disclose contraception method during
             screening and agree to continue to use that contraception method through the end of
             their participation in the study.

          -  Patients must have had all grossly visible papillary tumors removed within 90 days
             prior to registration or cystoscopy confirming no grossly visible papillary tumors
             within 90 days prior to registration.

          -  Patients with T1 disease must have cross-sectional imaging of abdomen/pelvis
             demonstrating no evidence of nodal involvement or metastatic disease (MRI or CT scan)
             within 90 days prior to registration. Patients with T1 disease must have re-resection
             confirming ≤ T1 disease within 90 days prior to registration.

          -  Patients must no have received prior intravesical BCG

        Exclusion Criteria:

          -  Have muscle-invasive or higher (≥T2) bladder cancer

          -  Unable to give informed consent

          -  Age 17 or younger

          -  Taking oral glucocorticoids at the time of registration

          -  Another cancer requiring active treatment (except basal cell carcinoma or squamous
             cell carcinoma of the skin)

          -  Patients at risk of pregnancy that are unwilling or unable to take effective
             contraception during the study period, or patients that are nursing during the study
             period. Women/ Men of reproductive potential must have agreed to use an effective
             contraceptive method or will be considered ineligible for study participation.

          -  Evidence of nodal involvement or metastatic disease (MRI or CT scan) within 90 days
             prior to registration

          -  History of prior intravesical BCG

          -  History of prior Rapamycin treatment